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Abstract
This review considers a way in which experimental data can be used to identify safe and effective antifungal regimens for humans.
The process begins with experimental models of invasive fungal infections that enable deﬁnition of optimal dosages and schedules of
antifungal drug administration to be deﬁned. These preclinical models also enable the identiﬁcation of drug exposure targets that are
associated with therapeutic outcomes of interest. Human pharmacokinetic variability results in a considerable range of drug exposures
following the use of ﬁxed antifungal drug regimens. This variability can be quantiﬁed using population pharmacokinetic modeling tech-
niques. Monte Carlo simulation can then be used to simulate pharmacokinetic variability and thereby estimate the proportion of
patients with a therapeutic outcome of interest. Effective and safe regimens can thus be studied appropriately in clinical settings. This
approach can, and should, be used to optimize antifungal therapy for a large number of clinical scenarios.
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Introduction
Invasive fungal infections are associated with signiﬁcant mor-
bidity and mortality [1,2]. Clinical trials of antifungal agents
are notoriously expensive and time consuming. Frequently
there is uncertainty regarding the optimal dosage and sche-
dule of administration for new agents and formulations, and
for novel indications of currently licensed agents.
Pharmacokinetics (the time-course of drug concentrations)
and pharmacodynamics (the relationship between drug con-
centrations and effect) are used to deﬁne optimal dosages
and schedules of antimicrobial compounds. Pharmacokinetic-
pharmacodynamic (PK–PD) relationships, deﬁned in experi-
mental systems, have been increasingly demonstrated to be
predictive of therapeutic outcomes in humans [3].
Here, we consider a way in which experimental antifungal
PK–PD relationships can be directly bridged to humans. The
bridging process enables candidate antifungal regimens that
are likely to be associated with optimal clinical effect to be
studied appropriately in clinical settings. Bridging experimental
data to humans is efﬁcient, cost effective, and likely to be
increasingly used in the future. Our review is predominantly
focused on studies of disseminated candidiasis because this
syndrome has been best studied. Importantly, however,
there is a pressing need to apply these same techniques to a
wide range of medically important fungi.
Overview of the Bridging Process
The steps involved in the in vivo-to-human bridging process
are summarized in Table 1. The major assumption is that the
organism rather than the host is the target of the antifungal
drug. The invading pathogen exists within a compartment
within a host (e.g. within the kidney of a mouse). The admin-
istration of drug to a host results in the fungus (at a particu-
lar site) experiencing some degree of drug exposure. The
magnitude of drug exposure that is experienced by the path-
ogen can be estimated and normalized using a measure of
drug potency (e.g. minimum inhibitory concentration (MIC),
minimum fungicidal concentration (MFC)).
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Because drug exposure is quantiﬁed with respect to the
invading pathogen rather than the host, the likely outcome
for the same organism growing in the same site in a human
host can be predicted. The drug exposure experienced by
the organism in the human host requires an understanding of
human PK. Population PK modeling techniques enable the
extent of human PK variability to be quantiﬁed. Monte Carlo
simulation allows an assessment of the impact of this PK var-
iability on clinical outcomes.
Models of Invasive Fungal Infections
Background
Laboratory animal models have been extensively used to
deﬁne PK–PD relationships. The use of other experimental
platforms (e.g. cell culture models, hollow ﬁber models) is
also possible and likely to be increasingly used as these mod-
els are further developed and validated. The importance of
robust and valid laboratory animal models of invasive fungal
infections is reﬂected by a concerted international effort that
is funded by NIH/NIAID to develop a range of models that
are predictive of human disease. The endpoint for models of
invasive fungal disease is usually the density of organisms
within a target organ, but a variety of measures are possible
if these are clinically meaningful and appropriately validated.
A key question of experimental models is the extent to
which they simulate human pathology and pathogenesis.
This is important for the bridging process because concen-
tration-effect relationships in the experimental model and
humans are assumed to be comparable. Such an assumption
is required because of the frequent inability to obtain phar-
macodynamic data from patients (e.g. obtaining a lung biopsy
from a neutropenic patient with thrombocytopenia). Further-
more, the site of infection may be an important determinant
of the antimicrobial effect. The best example of this is the
antibacterial agent, daptomycin, which was initially investi-
gated in a neutropenic thigh infection model [4], but found
to be ineffective for pulmonary infections because of inactiva-
tion by surfactant [5]. There are no similar examples con-
cerning antifungal agents, but it is reasonable to be
extremely cautious if the experimental infection site is differ-
ent from that observed in humans. It is probably not appro-
priate, for example, to use a kidney model of disseminated
TABLE 1. The steps in the bridging
process and an example of the
application of this technique to
deﬁne the optimal dosage of mica-
fungin for premature neonates
with haematogenous Candida
meningoencephalitis
Steps in the bridging process Insights from a recent bridging study
Develop an infection model A model of hematogenous Candida
meningoencephalitis was developed that
had many of the attributes of human disease
Characterize the exposure-response
relationships
The dose-response relationship was deﬁned
over multiple experiments. The endpoint
was the infectious burden within the
central nervous system
Deﬁne the pharmacokinetics The pharmacokinetics of micafungin in the
plasma of rabbits was deﬁned
Transform the dose-response relationship to
the relevant pharmacodynamic variable-response
relationship
The pharmacokinetic model in rabbits was
used to transform the dose of micafungin
to the AUC:MIC ratio, which was chosen
on the basis of previous dose fractionation
studies with caspofungin. The AUC:MIC
quantiﬁes drug exposure experienced by
the invading pathogen rather than the rabbit
Deﬁne the pharmacodynamictarget that is
associated witha successful outcome
Because there was no information on the
degree of fungal killing that was likely to be
relevant for human neonates, we choose
to employ near maximal antifungal effect
Deﬁne the population pharmacokinetics in the
population of interest
The population pharmacokinetics was
deﬁned in 21 neonates receiving micafungin.
This model provided an insight into the
expected drug exposures following the use
of different dosages and
schedules of administration
Use Monte Carlo simulation to reconstruct a
large simulated population that is based on
the original population
Monte Carlo simulation provided an insight
into the predicted decrement of fungal
burden in the brain following administration of
various dosages to neonates. These
analyses suggested that much larger dosages
(10–15 mg/kg) were required than is the
case for adults with disseminated
candidiasis (1–2 mg/kg)
Use the information for patients The bridging study has been used to deﬁne
the dosage of micafungin (10 mg/kg) that
will be used in a randomized clinical trial of
micafungin vs. amphotericin B for premature
neonates with hematogenous Candida
meningoencephalitis
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aspergillosis to predict the outcome of pulmonary infection
in humans.
Pharmacodynamic models of disseminated candidiasis
Robust pharmacodynamic models of disseminated candidiasis
are well established. For these models, the fungal density in
the kidney has proved to be an extremely useful endpoint.
The clinical relevance of this target organ is supported by
autopsy ﬁndings in patients with disseminated candidiasis,
where the kidney is frequently involved [6]. The kidney
model has been extensively used to study the pharmaco-
dynamics of the triazoles, polyenes and echinocandins [7–19].
The kidney model is not appropriate for all clinical ques-
tions because concentration-effect relationships may differ,
depending on the target organ. This is likely to be espe-
cially true for infections within sanctuary sites, such as
the central nervous system. A recent paper that described
the pharmacodynamics of micafungin in a rabbit model of
neonatal hematogenous Candida meningoencephalitis
(HCME); an experimental model of central nervous system
infection was required [20]. This model generated repro-
ducible infection within the cerebrum and cerebellum,
but the cerebrospinal ﬂuid was persistently sterile as is
frequently the case in neonates.
Pharmacodynamic models of invasive pulmonary
aspergillosis
Pharmacodynamic models of invasive pulmonary aspergillosis
(IPA) are far more challenging. Assessing fungal burden in the
lung using traditional culture techniques is problematic
because of difﬁculties in quantifying hyphal burden. These
difﬁculties are further compounded by the fact that IPA is
typically a focal disease, which may cause sampling errors if
only portions of the lung are resected and homogenized
(as in larger laboratory animals such as rabbits). Similarly,
ischemic necrosis and hemorrhagic infarction result in tissue
damage that may be disproportionate to the fungal burden
[21]. A further challenge is that the fungal burden from
tissue homogenates obtained early in the course of infection
may be misleading. This is because a proportion of inocu-
lated conidia lie dormant in vivo (and do not cause disease),
but germinate when the homogenized organ is plated, and
therefore contribute to estimates of overall fungal burden.
The use of other biomarkers, such as circulating fungal anti-
gens (e.g. 1,3 b-D glucan or galactomannan), represents an
ideal opportunity to characterize the pharmacodynamics of
antifungal agents against Aspergillus spp. [22,23]. An advantage
of these antigens is that they are not liberated by conidia and
therefore only reﬂect the fungal biomass responsible for tissue
damage. Measurement of Aspergillus nucleic acid in the lung is
also possible and increasingly used, but its value over and
beyond culture remains somewhat unclear. There is an ongo-
ing requirement to develop novel Aspergillus-related biomar-
kers that can be used to assess the activity of antifungal agents.
Limitations of pharmacodynamic models
A number of factors have an impact upon the ability to
elucidate concentration-effect relationships that are also
predictive for humans. Some pharmacodynamic studies use
only a single well-characterized laboratory strain, which
may leave questions as to the applicability of conclusions
for a wider population of organisms. In this regard, the
use of a standardized measure of antifungal potency (e.g.
MIC, MFC) broadens the applicability of study ﬁndings.
Typically, as the MIC increases, drug exposure must also
increase to generate a comparable effect. This normaliza-
tion does not account for all the observed variance, but
often accounts for a considerable portion. Laboratory ani-
mal models generally mimic acute rather that chronic inva-
sive syndromes; these syndromes are difﬁcult to simulate
in a reproducible manner. Other factors may also affect
the exposure response relationships, and subsequent con-
clusions of bridging studies; these include: (i) a delay in
the administration of antifungal therapy results in dimin-
ished antifungal effect [15,24]; (ii) organisms with a faster
rate of growth are killed more rapidly [16]; and (iii) the




The PK in the experimental system must be deﬁned to
enable drug exposure to be transformed from a measure of
drug exposure made with respect to the host (i.e. dose) to
one made with respect to the invading organism. As dis-
cussed above, quantifying drug exposure in terms of the
pathogen is the key step in the bridging process [25].
Pharmacokinetic models
Pharmacokinetic models may appear inscrutable. Neverthe-
less, mathematical models that are predictive of the time-
course of drug concentrations are critical for the elucidation
of pharmacodynamic relationships. If the pharmacokinetic
data or mathematical models are imprecise, all subsequent
conclusions are likely to be affected and may be incorrect.
The approaches and principles related to the design of phar-
macokinetic experiments in laboratory animals have been
previously reviewed [26]. Usually three–four dosages are
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studied to assess the degree of PK linearity. Samples are col-
lected throughout the dosing interval. For larger species,
such as rats and rabbits, serial samples can be collected from
the same animal. For mice, the collection of only a single
sample is usually possible, which means a serial sacriﬁce
design is required. PK experiments are difﬁcult to execute
precisely, but are of the utmost importance in deriving
accurate PK–PD relationships.
Tissue concentrations of antifungal agents
Much is made of the potential importance of measuring
tissue concentrations to fully understand the time course
of antifungal effect; this is an exceedingly complex topic,
and its importance is overstated in many cases. Frequently,
plasma concentrations are a perfectly acceptable surrogate
for concentrations at the site of infection, even in circum-
stances where the concentrations in tissues signiﬁcantly
deviate from those measured in plasma. For the bridging
process, an assumption is made that extent of tissue
penetration for the experimental system and the human
are comparable.
There are occasions where the measurement of tissue
concentrations enables a better understanding of the antifun-
gal effect. If concentrations of antifungal agents in plasma and
tissues scale proportionally, but there is signiﬁcantly delayed
trafﬁcking of drug into or out of tissues, then the antifungal
effect may become dissociated from plasma concentrations;
this phenomenon is called hysteresis. The echinocandins and
the triazoles are two classes of antifungal agents that exhibit
prolonged mean residence times within tissues, and the anti-
fungal effect may be best understood by considering tissue
concentrations over time [18,27]. For these compounds, the
tissues effectively act as a sump that slowly releases drug
back into plasma (Fig. 1). The relationship between plasma
and tissue concentrations of various clinical formulations of
amphotericin B is less well deﬁned. A further advantage of
studying tissue concentrations is that plasma pharmacokinet-
ics may be more accurately described, as demonstrated by
Louie et al., [18] who noted that the terminal half-life of ca-
spofungin was considerably longer when plasma and tissue
data were co-modeled.
Ideally, one wishes to measure the concentration of drug
directly at the level of its interaction with the microbiological
target. Microdialysis and tissue homogenates are two
approaches that are used for this purpose. The extent to
which drug concentrations in tissue homogenates reﬂect
concentrations at the site of infection is a function of the
drug and the pathogenesis of the infection in question. Tissue
homogenates represent a mixture of intracellular and extra-
cellular compartments. For compounds that distribute evenly
among these compartments, drug concentrations in tissue
homogenates provide an approximation of concentrations at
the site of infection. If the drug preferentially accumulates in
either the intracellular or extracellular compartment, the
estimates of drug exposure from tissue homogenates that
are experienced by the organism depends on the site of the
organism. If the pathogen exists at the same site as the drug,
tissue homogenates will result in an underestimate of effec-
tive concentrations because of the dilutional effect of the
other compartment. Conversely, if the pathogen site and the
site of drug accumulation are discordant then homogenates
may provide an overestimate of effective drug concentrations
because drug is ‘released’ by the other compartment in the
homogenization process.
Concentrations of drug can also be measured in bodily
ﬂuids such as epithelial lining ﬂuid of the lung (ELF), cerebro-
spinal ﬂuid (CSF), urine, and sinus aspirates. A decision must
be made whether these compartments are relevant to the
pathogenesis of the infectious process. Concentrations of
drug within the ELF, for example, may provide a reasonable
estimate of drug exposures that are useful for prophylaxis
and the treatment of early stages of invasive pulmonary
aspergillosis, but are probably of little relevance for the later
stages of disease, where the predominant pathological
changes occur within the pulmonary parenchyma rather than
within the alveolar airspace.
FIG. 1. The importance of tissue concentrations for an understand-
ing of antifungal effect. This ﬁgure depicts the concentration–time
proﬁle of caspofungin in the serum and kidneys of mice. Concentra-
tions are much higher in the kidney and persist long after serum
concentrations decline to undetectable levels. For caspofungin, the
antifungal effect is best understood by considering tissue concentra-
tions, although it is still possible to link serum concentrations with
the observed effect. This ﬁgure was produced using the pharmacoki-
netic program ADAPT II, and the pharmacokinetic model parameters
for caspofungin in a murine model of disseminated candidiasis
described by Louie et al. [18].
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Protein binding
The effect of protein binding on the activity of antifungal
agents is poorly understood. The degree of protein binding
that is characteristic of individual antifungal agents and classes
varies considerably. Flucytosine, for example, is negligibly
bound [28]. The triazoles display variable degrees of protein
binding ranging from low (e.g. ﬂuconazole 10%) [13], inter-
mediate (e.g. voriconazole c. 60%) [29] to high (e.g. isavuco-
nazole and posaconazole, >90%) [30,31]. The echinocandins
are extensively protein bound (>90%) [32]. The binding
properties of amphotericin B are very poorly understood.
There is little understanding of the effect of the drug binding
within tissues and the resultant impact on the antifungal
effect.
Most accept that only the concentration of free
(unbound) drug is pharmacologically active [25]. There is
little understanding of the way in which extensively bound
drugs engage with their target to induce an effect, but the
relative avidity of drug binding between the microbiological
target and the protein may be important. Total (i.e. bound
and free) plasma concentrations provide an approximation
of drug concentrations free to engage with the target. The
concentrations of free drug in plasma can be estimated by
using ultracentrifugation, or simply by correcting for the
estimated degree of protein binding [7]. The importance
of measuring free drug concentrations in plasma for a bet-
ter understanding of the observed antifungal effect is not
clear, although it does facilitate comparisons within a class
of agents. For the triazoles, for example, a free drug con-
centration (f)AUC:MIC of c.20–25 is associated with the
achievement of 50% of maximal effect in models of dis-
seminated candidiasis despite large differences in protein
binding (and therefore total drug AUC:MIC) within this
class [7,9,13].
Antifungal Pharmacodynamics
Pharmacodynamic index that best links drug exposure to
effect
The central tenant of modern antimicrobial pharmacody-
namics is that the shape of the concentration-time proﬁle
has a critical bearing on the antifungal effect. Three sum-
mary parameters are used to capture this information: the
time that serum drug concentrations are above a threshold,
the area under the concentration-time curve (AUC) and
the peak concentration. These measures are then related
to the MIC, which represents a standardized measure of
antifungal potency (see below). Consequently, the three
pharmacodynamic indices used to describe the time-course
of antifungal drug activity are T > MIC, AUC:MIC and
Peak:MIC [25].
Identifying the variable that drives effect is usually achieved
using dose fractionation studies in experimental models. Lim-
itations on the number of schedules of drug administration
to humans usually does not permit the relevant PK–PD
parameter to be elucidated in clinical contexts. An example
of an experimental dose fractionation study is shown in Fig-
ure 2, and the subsequent transformation that enables drug
exposure to be quantiﬁed with respect to the invading path-
ogen is shown in Figure 3.
If Peak:MIC is the pharmacodynamic parameter that best
links drug exposure with effect, the administration of less-
fractionated regimens is appropriate; for time-dependent kill-
ing, the administration of more fractionated regimens is
appropriate; for agents for which AUC:MIC drives effect, a
range of schedules of administration are potentially appropri-
ate. The triazoles are AUC:MIC driven [7,9,10,13,33]. The
echinocandins are either peak:MIC or AUC:MIC driven
[8,18,34–36]. The polyenes also exhibit concentration depen-
dent killing [12,37]. Discrepancies in the pharmacodynamic
parameter linked to effect can probably be attributed to sub-
tleties in study design, a detailed discussion of which is
beyond the scope of this review.
Minimum inhibitory concentration (MIC)
The MIC is an in vitro measure of antimicrobial potency
that has a central role in pharmacodynamics. Because the
absolute MIC value is exclusively dependent on the experi-
mental conditions (e.g. incubation time, medium etc.) it
does not necessarily have any inherent meaning; prior to
the standardization of testing methodology, antifungal MICs
varied by orders of magnitude [38]. Different experimental
conditions also account for discordant MICs as determined
by CLSI and EUCAST methodologies. For the bridging pro-
cess, an assumption is made that the same methodology is
used to determine the MIC in the experimental system and
patients.
In pharmacodynamics, the MIC simply serves as a scalar
to indicate that organisms with higher MICs require propor-
tionally higher drug exposures to derive the same overall
effect—its absolute value is of little importance, and using the
MIC in this manner is fraught with danger (e.g. designing dos-
ing regimens to ensure that concentrations exceed the MIC
for the dosing interval). An illustration of using the MIC as a
scalar was convincingly demonstrated in a rat model of
Pseudomonas aeruginosa that examined the survival in rats
infected with isogenic pairs of organisms with discordant
MICs [39]. Isolates with a higher MIC required propor-
tionally higher drug exposure to effect the same survival.
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A similar concept has subsequently been demonstrated for
disseminated candidiasis [16].
Deﬁning the Magnitude of the
Pharmacodynamic Variable that is
Associated with Endpoints of Interest
When the pharmacodynamic parameter that optimally links
drug exposure with the antifungal effect is known, the next
question is to determine the magnitude of that variable that
is associated with a high probability of achieving a successful
outcome (Fig. 4). This immediately raises the question as to
what constitutes a successful outcome in an experimental
model, and whether this endpoint is biologically (or clinically)
tenable. For invasive fungal infections, the use of any one of
a number of endpoints is potentially possible (e.g. reduction
in log10 CFU/g in kidney, decrement in galactomannan,
improved survival, decreased time to negative blood cul-
tures). The most appropriate endpoint depends on the
organism and the context. For a neutropenic host, for exam-
ple, a target associated with near maximal killing may be
desirable. In contrast, for non-neutropenic hosts, lesser
degrees of antifungal killing may sufﬁce, because of the addi-
tional antifungal effect of immunological effectors. The design
of many experimental models is such that sterilization of the
infection site is rarely observed, meaning that this cannot be
used as an outcome measure.
The most commonly employed endpoint for Candida mod-
els is some measure of logarithmic killing (e.g. a 1-log kill, 2-
log kill or 50% of maximal effect (ED50)). Pharmacodynamic
targets based on the ED50 have been correlated with clinical
outcomes for the triazoles [7,13,40,41]. We have also used
mathematical modeling techniques to identify the amphoteri-
cin B AUC:MIC that is associated with maximal suppression
of galactomannan in an in vitro cell culture model of the
human alveolus, and explored the implications of this value
for humans [23].
FIG. 2. An example of a dose fractionation study to determine the relevant pharmacodynamic variable that best links the drug exposure of
isavuconazole with the observed effect against Candida spp. The total dose is administered in differing schedules, and the effect in terms of the
decrement of Candida burden in the kidney is measured. Nonlinear regression is used to identify the best ﬁt of a sigmoid Emax model to the
data. For the candidacidal effect of isavuconazole, the AUC:MIC is the dynamically linked variable (Copyright ª American Society for Microbiol-
ogy, Antimicrobiol Agents and Chemotherapy, 2009).
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There is no way of knowing whether a pharmacodynamic
target is necessarily meaningful for clinical contexts—this
must be determined by extensive cross validation with clini-
cal data, as is best illustrated with ﬂuconazole [13,40,41].
In this regard, the bridging process should be viewed as an
iterative exercise, whereby clinical data also inform experi-
mental model design and endpoint selection.
In some clinical contexts, it may be possible to identify
the magnitude of drug exposure that is associated with high
probability of successful outcome. This is possible for ﬂuco-
nazole for the treatment of both superﬁcial and invasive can-
didiasis [40–43]. Because the daily dosage and the mean
AUC of ﬂuconazole are very similar, it is possible to esti-
mate the AUC:MIC if the dose and the pathogen MIC are
known. Using this approach, an AUC:MIC of >25–50 (CLSI)
[41] or >100 (EUCAST) [42] is associated with a high
probability of therapeutic success. A limitation of these
studies is that the estimates of AUC:MIC are potentially
imprecise because they are all extrapolated from dose alone
or point estimates of clearance. Without direct measure-
ment of drug concentrations, the extent of inherent pharma-
cokinetic variability is undeﬁned, and the impact of this
variability on clinical outcome is not apparent.
Bridging the Experimental Results to
Humans
Once the pharmacodynamic target of interest is deﬁned in an
experimental system, the next step is to examine how that
target can be achieved in either an individual or a popula-
tion of patients. For an individual patient, this problem is
addressed with antifungal therapeutic drug monitoring; this
topic has been recently reviewed [44,45] and will not be
discussed further. The fraction of patients in a population
achieving a speciﬁc exposure target depends on the extent of
PK variability within that population. This can be quantiﬁed
with population PK models and the consequences of this vari-
ability can be further explored using Monte Carlo simulation.
Population pharmacokinetics
Population PK differs from conventional PK by explicitly
allowing and estimating inter-patient PK variability in a single
FIG. 4. Deﬁning the pharmacodynamic target. In this example, the
endpoint was a 2-log drop in the fungal density of Candida spp. in
the kidney. The circles represent groups of eight mice receiving ﬂu-
cytosine and the solid line is a logistic regression model that links
drug exposure with the probability of attaining the target (i.e. achiev-
ing a ‡2-log drop). When serum concentrations were above the
MIC for ‡45% of the dosing interval, there was a 95% probability of
achieving this target in mice. This pharmacodynamic target can then
be taken forward and applied in clinical contexts (Copyright ª
American Society for Microbiology, Antimicrobiol Agents and
Chemotherapy 50, 3680–3688, 2006).
FIG. 3.When the pharmacodynamic parameter that best links drug
exposure with the observed effect is known (see Fig. 2), exposure-
response relationships can be transformed from measures of drug
exposure quantiﬁed with respect to the host (i.e. dose mg/kg,
Panel a) to a measure quantiﬁed with respect to the invading patho-
gen (in this example of ﬂucytosine the fraction of the dosing interval
that serum concentrations are above the minimum inhibitory
concentration, Panel b). (Copyright ª 2005 Infectious Diseases
Society of America)
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step. When any pharmacological agent is administered to a
population of patients, variability in drug exposure is
observed (Fig. 5). Depending on the exposure-effect and
exposure-toxicity relationships, this variability may have a
signiﬁcant impact upon clinical outcome. A proportion of
patients receiving a standard ﬁxed dosage will inadvertently
have low drug exposures and be at increased risk of
concentration-dependent failure, while others with high
exposures are at increased risk of toxicity.
A portion of the observed variability in drug handling may
be understood in terms of covariates (or ﬁxed effects) such
as weight, surface area, ethnicity, CYP genotype and gender.
Covariates that explain variability can be incorporated into
structural population PK models to help explain the
observed variance (e.g. weight can be linked to clearance if
heavier patients have a higher rate of clearance; see for
example [46]). A further portion of observed variability
results from errors inherent to drug measurement, dosing
and sampling times. Even when all known covariates have
been entered, a degree of inter-individual variance remains
(‘true’ between-patient variance). For a majority of drugs,
this variance is extensive (Fig. 5), and for some agents this
has important clinical consequences.
The design of clinical PK studies is critical. D-optimal
design theory can be used to identify information-rich sam-
pling times, thus enabling the population pharmacokinetics to
be described with a minimal number of samples; this is obvi-
ously important for critically ill patients for whom intensive
sampling is not appropriate [47]. The number of patients
required to describe the population PK is difﬁcult to predict,
but parameter values usually begin to stabilize after approxi-
mately 25 patients. Population PK models provide summary
statistics (e.g. measures of central tendency, dispersion and
covariance) for each of the PK model parameters (e.g. clear-
ance, volume of distribution, intercompartmental rate con-
stants) that are used to describe drug behavior in a
population.
Monte Carlo simulation
The use of simulation techniques to address problems that
are too complicated for an analytical solution, or too risky
for experimentation, can be traced to work of the physicists
von Neuman, Fermi and Ulam, working on nuclear weapon
projects in the Los Alamos National Laboratory in the late
1940s. Monte Carlo simulation refers to a process of
repeated random sampling from a known distribution. The
term ‘Monte Carlo’ refers to the casino in recognition of the
repeated and random nature of this process. Monte Carlo
simulation is used in a wide number of disciplines including
physics, ﬁnance and engineering, and is increasingly used in
pharmacology [48].
Monte Carlo simulation provides an estimate of the likely
outcomes when a large population of patients is administered
a given dosage and schedule. These predictions are a direct
reﬂection of the population that was used to derive the pop-
ulation pharmacokinetic model. If a relatively small number
of patients with limited differences are studied (e.g. 10–20
healthy Caucasian male volunteers) this will likely result in
poor estimates of the extent of variability in drug exposures
that can be expected as one moves to a sick and more
diverse clinical population. This may have important implica-
tions for estimates of the proportion of patients with poor
clinical outcomes (due to suboptimal drug exposures) or
toxicity (due to unanticipated high drug exposures).
Simulated patients are created by a computer by supplying
a measure of central tendency (e.g. mean or median) and
dispersion for each PK parameter; these estimates are
obtained from the output of a population PK model. Various
parameter distributions within the population (e.g. normal or
log normal distributions) are explored in the simulation
process, with the aim that the simulated population has
summary statistics very similar to those of the original
starting population.
FIG. 5. An example of variability in drug exposure that is deﬁned
using population pharmacokinetics. A population pharmacokinetic
model can be used to describe the extent of variability that can be
expected when a large population of patients is administered a drug
at a given dosage and schedule. In this example a relatively large
range of AUCs are seen when micafungin is administered to children.
Depending on the agent and the organism, this variability may have
an effect on the probability of clinical outcome and the probability of
toxicity (Copyright ª American Society for Microbiology, Antimicro-
biol Agents and Chemotherapy 51, 3714–3719, 2007).
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Once the simulated population has been constructed, a
candidate regimen is administered to each simulated patient
and the resultant concentration-time proﬁle and drug expo-
sure (i.e. AUC:MIC, T > MIC, peak:MIC) are calculated. The
outcomes are then tabulated and outcomes of interest (e.g.
proportion of simulated patients with T > MIC 50% of the
dosing interval) are determined. The predicted drug expo-
sure for individual patients can also be used to calculate the
predicted outcome if the pharmacodynamic relationships are
known (Fig. 6). Different dosages and schedules of adminis-
tration can then be explored to deﬁne regimens that are
associated with a high probability of success (and/or a low
probability of toxicity). Outcome measures can also be con-
sidered with respect to the underlying distribution of MICs
to obtain an overall prediction of drug effect (Fig. 7).
Population pharmacokinetics and Monte Carlo simulation
enable a detailed assessment of the consequences of PK vari-
ability. A drug regimen must be safe and effective for the
majority of that population, not just for the population mean
or median. If one simply aligns the pharmacodynamic target
from the experimental system with the mean population
FIG. 6. An example of the use of Monte Carlo simulation to deﬁne an optimal dosage of micafungin for human neonates. Here, human popula-
tion pharmacokinetic parameters for neonates have been inserted into the simulator. The administration of various human dosages (shown in
Panels A–E) produces a range of AUCs because of human pharmacokinetic variability (as shown in Fig. 4.). Because the AUC can be linked with
the antifungal effect, the outcome of various dosages and the impact of human pharmacokinetic variability can be simulated. In this example, the
predicted fungal burden in the brains of human neonates progressively falls with the administration of higher dosages. These simulations can be
used to choose a dosage for clinical trials that is likely to be associated with near maximal effect for a sufﬁciently large proportion of the popula-
tion (reproduced with permission, ª 2008, Infectious Diseases Society of America).
FIG. 7. Monte Carlo simulations to explore the optimal dosage of
ﬂucytosine against Candida albicans in a disseminated candidiasis
model. The MIC distribution is shown (solid circles). The open sym-
bols represent the proportion of patients with concentrations ‡MIC
for 45% of the dosing interval at each MIC level. As the MIC rises,
fewer patients attain the target. These simulations can be used to
deﬁne the most effective regimen for a population of patients, given
a known MIC distribution that will be encountered in that popula-
tion (Copyright ª American Society for Microbiology, Antimicrobiol
Agents and Chemotherapy 50, 3680–3688, 2006).
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drug exposure, then (depending on the shape of the popu-
lation distribution) approximately half of the population
will have a suboptimal drug exposure, which is clearly
unacceptable.
Applications of the Bridging Process
There are two broad applications of the bridging process for
antifungal agents: (i) provision of decision support for the
setting of antifungal susceptibility breakpoints; (ii) the identiﬁ-
cation of safe and effective antifungal drug regimens for
patient populations. In terms of the former, in vivo-to-human
bridging studies have been performed to identify potential in
vitro susceptibility (EUCAST) breakpoints for ﬂucytosine [16].
EUCAST has embraced the bridging concept to aid in the
setting of antimicrobial breakpoints.
Bridging techniques can also be used to identify optimal
dosages for humans. A recent example of this is the use of a
rabbit model of neonatal HCME to identify a dosage of mica-
fungin likely to be associated with near maximal antifungal
activity; this study suggested that c.10 mg/kg is associated
with near maximal antifungal activity for a majority of patients
and is currently being used in a clinical trial [20]. Importantly,
this dosage is higher than the 1–2 mg/kg currently used for
adult patients; if a similar dosage were to be used in neonates,
a large proportion of neonates may fail therapy resulting in an
otherwise effective agent being abandoned.
Conclusions
Bridging techniques are likely to be increasingly used in
translational pharmacology because this process enables the
efﬁcient use of limited resources. Bridging provides a way in
which optimal regimens can be identiﬁed in a timely manner.
This process employs many of the techniques that are cur-
rently required for the drug development process; the key is
the integration of these phases. Preclinical PK–PD models
and relatively small well-designed population PK studies can
be combined to design deﬁnitive phase III and IV trials. Bridg-
ing techniques can and should be used for new antifungal
compounds and for the use of currently licensed compounds
for special populations.
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